Filana Advances Simufilam with Preclinical Epilepsia Data, Q1 Cash at $86.6M
Filana Therapeutics ended Q1 with $86.6M cash, no debt and forecasts $47-50M by June 30 after net operating cash burn of $8.9M, while reducing R&D and G&A expenses by 67% and 39% year-over-year following Alzheimer’s program phase-out. The company is advancing simufilam for TSC-related epilepsy, published preclinical Epilepsia data showing dose-dependent seizure attenuation in mice and plans to resolve FDA’s clinical hold with additional studies and protocol revisions.
1. Q1 Financial Results and Cash Guidance
Filana ended Q1 2026 with $86.6 million in cash and cash equivalents and no debt, down from $95.5 million at December 31, 2025. The company used $8.9 million in operating cash during the quarter, posted a net loss of $10.3 million ($0.21 per share), and expects cash of $47-50 million by June 30, 2026.
2. Expense Reductions Driving Lower Burn
Research and development expenses declined 67% to $4.5 million compared to Q1 2025, reflecting completion of the Alzheimer’s disease program, while general and administrative costs fell 39% to $6.6 million due to the absence of prior legal loss contingencies. Filana projects first-half 2026 operating cash use of $14-17 million plus a potential $31.25 million litigation-related payment.
3. Simufilam Preclinical Data and Conference Presentation
Filana published preclinical simufilam data in Epilepsia demonstrating dose-dependent attenuation of seizure progression in a severe TSC mouse model and presented its TSC-related epilepsy program overview at Eilat XVIII. These findings support the biological rationale for targeting filamin A in TSC-related epilepsy, which affects an estimated 45,000 patients in the U.S.
4. Regulatory Strategy for Clinical Hold
The company is actively working to address the FDA’s clinical hold by preparing additional preclinical data submissions and modifying trial protocols. The timeline for initiating clinical trials will depend on the FDA’s review and acceptance of the proposed materials.